TEMPE, Ariz., Oct. 21, 2025 /PRNewswire/ GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced the interim results from its ROADS clinical trial (Randomized Controlled Trial of Resection [Surgery] and GammaTile® versus Standard of Care) in patients with operable, newly diagnosed brain metastases.
Immediate, targeted radiation at the time of surgery reduces the risk of tumor recurrence or death by greater than 50% compared to standard of care in early clinical data readout.
The trial, which completed randomization of 230 patients over 30 leading cancer centers in the United States in August 2025, evaluated whether implanting GammaTile – a form of brain tumor radiation that begins immediately at the time of surgery, with no waiting or time lost – could improve outcomes compared with the current standard of care (surgery followed by postoperative external beam stereotactic radiation therapy [SRT]). The standard approach requires a recovery period before radiation can begin, during which remaining microscopic tumor cells may regrow.